Results 181 to 190 of about 18,118,892 (286)

Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran

Applied Health Economics and Health Policy, 2018
K. Lankarani, S. Ghahramani, N. Moradi, H. Shahraki, F. Lotfi, B. Honarvar   +5 more
semanticscholar   +1 more source

Stage‐Dependent β‐Synuclein Links MRI and Cognitive Decline in Alzheimer's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Synaptic degeneration drives cognitive decline in Alzheimer's disease (AD), but synaptic biomarkers are scarce. Brain‐enriched β‐synuclein emerged as a synaptic damage marker. We investigated its diagnostic, prognostic, and structural correlates across the AD continuum.
Ulaş Ay, Merve Alaylioglu, Erdi Sahin, Sanem Sultan Yoruk Oner, Gulce Iskan, Gulce Cosku Yilmaz Cakan, Gozde Kizilates‐Evin, Emre Hari, Elif Kurt, Erdinc Dursun, Basar Bilgic, Hasmet Hanagasi, Hakan Gurvit, Tamer Demiralp, Duygu Gezen‐Ak, Bedia Samanci   +15 more
wiley   +1 more source

From toxicity to immunity: Evaluating CAR-T and conventional therapies in multiple myeloma through quality-adjusted life year (QALY) outcomes. [PDF]

Ther Adv Hematol
Itez GG, Sunguroğlu A.
europepmc   +1 more source

Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone.

Journal of Comparative Effectiveness Research, 2017
B. Németh, A. Molnár, R. Akehurst, M. Horváth, K. Kóczián, G. Németh, A. Gotze, Z. Vokó   +7 more
semanticscholar   +1 more source

Monetary evaluation of quality-adjusted life year in patients with malignant tumor in China: Willingness-to-pay analysis. [PDF]

Medicine (Baltimore)
Huang L, Peng X, Zhang J, Sun L.
europepmc   +1 more source

Estimating the Quality-Adjusted Life-Year Loss due to Fatal and Nonfatal COVID-19 Outcomes across US States and Counties, July 2020 to December 2022. [PDF]

MDM Policy Pract
Mikdashi F, Murray-Watson RE, Lopes R, Bilinski A, Yaesoubi R.   +4 more
europepmc   +1 more source

Quantifying Disease Severity in Health Technology Assessment in Japan: A Retrospective Analysis Using Quality-Adjusted Life-Year Shortfalls. [PDF]

J Health Econ Outcomes Res
Enami M, Yuasa A, Ikeda S.
europepmc   +1 more source

Crisis Preparedness by Simulating Quality-Adjusted Life-Year Loss in Patients with End-Stage Renal Disease due to Kidney Transplantation Suspensions. [PDF]

MDM Policy Pract
Bonnemains V, Le Borgne F, Dantan E, Pastural M, Giral M, Couchoud C, Foucher Y.   +6 more
europepmc   +1 more source

Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality‐adjusted life‐year analysis

Cancer, 2016
Chiranjeev Sanyal, A. Aprikian, F. Cury, S. Chevalier, A. Dragomir   +4 more
semanticscholar   +1 more source

Benefits beyond health in the willingness to pay for a quality-adjusted life-year. [PDF]

Eur J Health Econ
de Vries LM, Brouwer WBF, van Baal PHM.
europepmc   +1 more source